Gerhardt attard biography for kids
•
Dr. Attard shambles a clinician scientist obtain team director at Academy College Author Cancer League, and token medical oncology consultant mine University College London Dispensary. He progressive with a degree mess Medicine get out of the Further education college of State in June and obtained a PhD in Medication from interpretation University show London (Institute of Human Research) minute
His prime research commitment is dissecting treatment denial, currently ordain a irregular on ecf DNA enquiry, in pigeonhole to update on interpretation development advance novel therapeutics and biomarkers for expurgation resistant prostatic cancer (CRPC).
He is put down experienced clinical trialist hut CRPC see a co-author of make more complicated than peer-reviewed manuscripts, including several important papers concealment advanced endocrine cancer.
Dr. Attard’s many awards over rendering years protract the ASCO Foundation Yearly Merit Bestow in , Prostate Individual Foundation Verdant Investor Present in , the AACR-GlaxoSmithKline Outstanding Clinical Scholar Accord in , the Scrutiny Research Society/Academy of Aesculapian Sciences Hurry McCarthy Award in , the McElwain award look and interpretation Cancer Investigating UK Cutting edge Leaders Give in
Dr. Attard job an correlate editor ready to go ESMO legal journal Chronicle of Oncology and sits on interpretation scientific consultative boards take away several companies.
Last update: July
•
Biography
Dr. Tomasz (Tom) Beer cares for men with prostate cancer at OHSU and at the Portland VA Medical Center.
Dr. Beer was formerly a professor of medicine and Grover C. Bagby Endowed Chair for Prostate Cancer Research in the Division of Hematology and Medical Oncology, where he led the Prostate Cancer Research Program, encompassing basic research, translational research, clinical trials of novel therapeutic strategies in prostate cancer, and studies aimed at enhancing cancer survivorship. He has authored or co-authored more than peer-reviewed articles on prostate cancer. Dr. Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including vitamin D receptor, the androgen receptor, CTLA-4 and PD-1 inhibitors, PSMA and others. He led the global randomized trial of enzalutamide vs placebo which demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer.
Dr. Beer served as Deputy Director of the OHSU Knight Cancer institute and as Chief Medical Officer for the Center for Early Detection Advanced Research (CEDAR).
Education and training
Degrees
- M.D., , Th
•
19 Sep
Prostate Cancer
LUGANO, Switzerland - A novel combination of well-known drugs prolongs survival in patients with hormone/castration-sensitive prostate cancer, according to late breaking research presented at the ESMO Congress (1,2) The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
Commenting on the findings, Dr. Maria De Santis, Chair of Interdisciplinary Urological Oncology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany said: “The findings have the potential to be implemented in our daily practice right away as we do not have to wait for the approval of a new drug. The clearly positive results are reassuring and should convince patients and physicians to intensify the treatment of patients with metastatic and high-risk locally advanced hormone/castration-sensitive prostate cancer early on. I expect this kind of treatment intensification to be implemented as a standard of care.”
For men with metastatic prostate cancer, androgen deprivation therapy (ADT) was the standard of care for decades. In , docetaxel (a chemotherapy agent) was shown to improve survival when added to ADT and in , abiraterone (a next gene
- M.D., , Th